• 1
    Parry CM, Hien TT, Dougan G, et al. Typhoid fever. N Engl J Med 2002; 347:17701782.
  • 2
    Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ 2004; 82:346353.
  • 3
    Centers for Disease Control and Prevention. Typhoid immunizations recommendations of the advisory committee on immunization practices (ACIP). MMWR 1994; 43:17.
  • 4
    Spira AM. Preparing the traveller. Lancet 2003; 361:13681381.
  • 5
    Lankester T. Health care of the long-term traveller. Travel Med Infect Dis 2005; 3:143155.
  • 6
    Centers for Disease Control and Prevention. Health Information for International Travel 2005-2006. Atlanta, GA: US Department of Health and Human Services, Public Health Service, 2005.
  • 7
    Steinberg EB, Bishop R, Haber P, et al. Typhoid fever in travelers: who should be targeted for prevention? CID 2004; 39:186191.
  • 8
    Acharya IL, Lowe CU, Thapa R, et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. N Engl J Med 1987; 317:11011104.
  • 9
    Klugman KP, Gilbertson IT, Koornhof HJ, et al. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet 1987; 11651169.
  • 10
    Yang J, Acosta CJ, Guoai S, et al. A mass vaccination campaign targeting adults and children to prevent typhoid fever in Hechi. BMC Public Health 2005; 5:49.
  • 11
    Keitel WA, Bond NL, Zahradnik JM, et al. Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines. Vaccine 1994; 12:195199.
  • 12
    Plotkin SA, Bouveret-Le Cam N. A new typhoid vaccine composed of the Vi capsular polysaccharide. Arch Intern Med 1995; 155:22932299.
  • 13
    Hessel L, Debois H, Fletcher M, et al. Experience with Salmonella typhi Vi capsular polysaccharide vaccine. Eur J Clin Microbiol Infect Dis 1999; 18:609620.
  • 14
    Aventis Pasteur. Typhim Vi polysaccharide vaccine. Prescribing Information. 2004.
  • 15
    Begier EM, Burwen DR, Haber P, et al. Postmarketing safety surveillance for typhoid fever vaccines from the vaccine adverse event reporting system, July 1990 through June 2002. CID 2004; 38:771779.